OSSIO Introduces Small OSSIOfiber Suture Anchors

OSSIO Inc. has expanded its best-in-class soft-tissue fixation portfolio with the launch of OSSIOfiber 2.5mm Suture Anchors, which aim to improve several surgical procedures, including Brostrom repair for lateral ankle instability.

“With these new small OSSIOfiber Suture Anchors, I can approach a familiar procedure with the same technique I’ve always trusted, only now I’m using a smaller, stronger, smarter material that I believe is the future of orthopedics,” said Thomas Philip San Giovanni, M.D., a board-certified orthopedic surgeon affiliated with Baptist Health South Florida. “Outcomes with this novel material aren’t just equivalent, they’re better in my experience.”

Designed for procedures like Brostrom repair—a standard surgery to fix lateral ankle instability—OSSIOfiber 2.5mm Suture Anchors offer 55% greater pull-out strength over the market-leading 2.4mm bio-composite suture anchor.

As with the company’s overall product portfolio, OSSIOfiber Suture Anchors feature a novel material engineered without metal to integrate into bone, leaving a more natural orthopedic landscape with minimal risk of adverse reactions.

Challenging Fixation Standard While Accommodating a Procedural Standard

The device’s physical design supports various standard surgical techniques for fixating sutures or soft tissue with a procedural workflow and instrumentation set that are both familiar and efficient, including drill bits and a slotted drill guide for easy drilling and anchor insertion. In addition, its versatile configuration options—specifically, unloaded and pre-loaded devices—allow for technical flexibility and respect varying surgeon preferences, according to the company.

“In launching our latest OSSIOfiber platform, we’ve brought to market the first small, fully bio-integrative suture anchor, which outperforms current options for lateral ankle instability and other repairs,” OSSIO CEO Brian Verrier explained. “With this anchor, surgeons can perform these procedures with less impact and better results for patients, while adding fixation strength. The device also rounds out our best-in-class line of implants for soft tissue fixation.”

OSSIOfiber Suture Anchors (2.5mm–3.5mm range) are used for suture or tissue fixation in the foot, ankle, knee, hand, wrist, elbow, and shoulder in adults and children (2–12 years) and adolescents (12–21 years) in which growth plates have fused or in which growth plates will not be crossed by fixation, in numerous specific orthopedic indications:

• Foot/Ankle: Lateral stabilization, medial stabilization, achilles tendon repair, metatarsal ligament repair, Hallux Valgus reconstruction, digital tendon transfers, mid-foot reconstruction.
• Knee: Medial collateral ligament repair, lateral collateral ligament repair, patellar tendon repair, posterior oblique ligament repair, iliotibial band tenodesis, joint capsule closure.
• Hand/Wrist: Scapholunate ligament reconstruction, carpal ligament reconstructions, repair/reconstruction of collateral ligaments, repair of flexor and extensor tendons at the PIP, DIP and MCP joints for all digits, digital tendon transfers.
• Elbow: Biceps tendon reattachment, ulnar or radial collateral ligament reconstruction, lateral epicondylitis repair (Tennis Elbow).
• Shoulder: Rotator cuff repairs, Bankart repair, SLAP lesion repair, biceps tenodesis, acromio-clavicular separation repair, deltoid repair, capsular shift or capsulolabral reconstruction.

Based on intelligent bone regeneration technology, OSSIOfiber implants combine mechanical strength and natural healing in a bio-integrative design. Their proprietary mineral fiber matrix enables rapid bone in-growth, regeneration, and replacement—a new way for orthopedic surgeons to restore stability and mobility while leaving nothing permanent behind.

OSSIOfiber implants represent an alternative to metal, absorbable, and allograft fixation devices. Reportedly the most significant advancement in orthopedic fixation technology in more than a century, this medical technology can potentially address an increasingly wide array of surgical applications due to the proprietary “know-how” to manufacture limitless variations.

Notably for U.S. healthcare providers and payors, OSSIOfiber implants use existing reimbursement codes and surgical techniques. Through June 2025, more than 50,000 OSSIOfiber implants have been used in the United States. Founded in 2014, OSSIO conducts product development in Caesarea, Israel, and commercial operations from Woburn, Mass.